SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Trey Yon who wrote (548)3/29/1997 10:39:00 AM
From: per strandberg   of 6136
 
Trey,

Because of inherent resistance problems with all PIs, regularly changing the PI(s) used will be the best way to reduce viral load. Compare this with resistance to antibiotics. The Vertex product will be a complement, rather than a panacea to cure AIDS. It's my belief that all PIs will get a share of the market depending on their efficacy and tolerance, not marketing pressure.

Then we have the almost virgin field of combining two or more PIs.
Who knows, Viracept and VX487 may be an outstanding combination.

ps
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News